Safety and Efficacy of Mobic® Ampoules in the Initiation of Treatment of Painful Exacerbations of Osteoarthritis, Rheumatoid Arthritis and Other Similar Painful Inflammatory Conditions

Completed

• Conditions: Arthritis, Rheumatoid
• Interventions: Drug: Meloxicam

• Registration Number: NCT02184052
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

Study to determine the safety and efficacy of Mobic® ampoules in the initiation of treatment of painful exacerbations of osteoarthritis, rheumatoid arthritis and other similar painful inflammatory conditions.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-07
• Primary Completion: 2005-03
• Status Verified: 2014-07
• Study First Submitted: 2014-07-03
• Study First Submitted QC: 2014-07-08
• Last Update Submitted: 2014-07-08
• Study First Posted: 2014-07-09
• Last Update Posted: 2014-07-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 121

Inclusion Criteria

• Painful acute exacerbations of inflammatory rheumatism (rheumatoid arthritis and ankylosing spondylitis), painful acute exacerbations of osteoarthritis and other similar conditions requiring acute treatment with an anti-inflammatory drug

Exclusion Criteria

• none

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Meloxicam	Meloxicam	-

Primary Outcome Measures

Name	Time	Method
Overall assessment of degree of pain on a 3-point scale	up to 3 days

Secondary Outcome Measures

Name	Time	Method
Number of patients with adverse events	up to 3 days